Our best Wall Street picks for 2024

Here are our top U.S. stock picks for 2024—one each from our Conservative, Aggressive and Income portfolios.
All three are in a strong position to fuel your returns, not only in 2024 but–more importantly–for many years to come. Moreover, their position as market leaders will help… Read More

Pfizer shifts to post-pandemic growth

Pfizer’s shares are down 45% in the past year due to lower demand for its COVID-19 treatments as the pandemic eases. However, new products from its acquisition of Seagen and its high research spending, generally, should spur long-term growth and your dividends.
PFIZER INC. $28 is… Read More

Pfizer ready for post-COVID sales

Pfizer recently cut its outlook for 2023 due to declining demand for its COVID-19 vaccines and treatments. However, the company is using the huge profits it earned on those products to buy other drugmakers with promising products.
We feel these moves, as well as Pfizer’s own… Read More